Printer Friendly

Eisai Announces Results of Overseas Clinical Trials of Donepezil in Treating Vascular Dementia.

Tokyo, Japan, Mar 17, 2006 - (JCN) - Eisai announced the results of its latest clinical trials of donepezil in patients with vascular dementia (VaD) on March 16.

Randomized, double-blinded tests were conducted in nine countries with patients with VaD and with no prior diagnosis of Alzheimer's disease. Compared with a placebo group, the subjects receiving donepezil showed significant improvement in cognitive functions but not in global functions.

No statistically significant difference in the occurrence of adverse effects was observed. However, the mortality rate was higher in the donepezil group than the placebo one.

In the US, Japan and the EU, donepezil, under the trade name Aricept, is currently indicated for the treatment of mild to moderate Alzheimer's disease but not for VaD. In the meantime, it is available for the treatment of VaD in India, New Zealand, the Philippines, Romania, South Korea and Thailand.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Mar 17, 2006
Previous Article:Kobayashi Pharmaceutical Introduces New OTC Anemia Treatment.
Next Article:Consumer Finance Companies Set Self-Imposed Limits on TV Advertising.

Related Articles
Eisai Files Application Seeking Additional Indication for ARICEPT in US.
Eisai Files Application Seeking Additional Indication for ARICEPT in Europe.
Eisai Recieves Positive Opinion for Inovelon(R) Marketing Authorization from European Committee for Medicinal Products for Human Use (CHMP).
Eisai Announces Inovelon(R) Receives Marketing Authorization Approval from European Commission.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |